Shanghai Chempartner Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising HER2 (erbB2) or tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to eribulin through a linker reported to be useful for the treatment of cancer.

Jiangxi Kerui Pharmaceutical Co. Ltd. has patented potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators. They are reported to be useful for the treatment of anxiety disorders, depression, pain, focal seizures and tonic clonic epilepsy.

Researchers from Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have disclosed tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors. They are reported to be useful for the treatment of cancer, metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), obesity and diabetes.

Morphic Therapeutic Inc. has identified integrin αvβ8 antagonists. They are reported to be useful for the treatment of cancer.

Abbisko Therapeutics Co. Ltd. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors designed for use in the treatment of cancer.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed amide-substituted cycloalkyl compounds acting as relaxin receptor 1 (RXFP1; LGR7) agonists potentially useful for the treatment of heart failure and hypertension.

A patent from Gilead Sciences Inc. has divulged GTPase KRAS (G12D mutant) inhibitors and proteolysis targeting chimeras (PROTACS) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS (G12D mutant)-targeting moiety through linker.

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis of Parkinson’s disease.

Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have patented new Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists designed for use in the treatment of atopic dermatitis, irritable bowel syndrome, metabolic syndrome, migraine, pain, neuropathic pain, rheumatoid arthritis and urticaria, among others.

Haisco Pharmaceutical Group Co. Ltd. has reported fibroblast growth factor receptor 2 (FGFR2) and FGFR3 inhibitors potentially useful for the treatment of cancer.